Ireland· IE-PA-EU/1/18/1330/001-004
Emgality
A galcanezumab product containing galcanezumab, registered in Ireland by Eli Lilly Nederland B.V..
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- GALCANEZUMAB
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Ireland (IE)
- ATC code
- N02CX08
- ATC class
- Galcanezumab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1330/001-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Galcanezumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMGALITYEli Lilly Nederland B.V., Utrecht
- United StatesEMGALITYEli Lilly and Company
- CanadaEMGALITYELI LILLY CANADA INC
- FinlandEmgalityEli Lilly Nederland B.V.
- IcelandEmgalityEli Lilly Nederland B.V.*
- SwitzerlandEmgality
- SpainEMGALITY 120 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAEli Lilly Nederland B.V.
- BelgiumEmgality 120 mgEli Lilly Nederland
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emgality
- Liechtenstein · Emgality
- Norway · Emgality
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/872875ba-feed-4ac5-a952-1e57688f35a3 GET /v1/drugs/872875ba-feed-4ac5-a952-1e57688f35a3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"N02CX08"
],
"strength": null,
"pa_number": "EU/1/18/1330/001-004",
"substances": [
"GALCANEZUMAB"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "14/11/2018",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about galcanezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.